COMMUNIQUÉS West-GlobeNewswire

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront [...]
Valneva publiera ses résultats financiers consolidés du premier trimestre le 13 mai 2026
06/05/2026
Lyon (France), le 6 mai 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers du premier trimestre le mercredi 13 [...]
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
06/05/2026
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - [...]
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed [...]
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
06/05/2026
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell’s next generation personalized immunotherapy [...]
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
06/05/2026
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to [...]
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
06/05/2026
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Immunocore reports first quarter financial results and provides a business update
06/05/2026
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles [...]
Immusoft to Present Data Highlighting Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial at ASGCT 2026
06/05/2026
SAN FRANCISCO, May 06, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that Scott McIvor, Chief Development Officer at Immusoft, [...]
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
06/05/2026
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will [...]
Crescent Biopharma to Present at May Investor Conferences
06/05/2026
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Medline Reports First Quarter 2026 Results
06/05/2026
Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5 [...]
Glass House Brands Announces Application for DEA Registration of Certain Medical Operations
06/05/2026
LONG BEACH, Calif. and TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) today announced that it has submitted [...]
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
06/05/2026
First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued [...]
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary
06/05/2026
Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards first-in-human studies Cambridge, UK, 6 th May 2026 Immutrin Ltd, (“Immutrin” [...]
Cronos Expands Pre-Roll Portfolio with Spinach STIX®
06/05/2026
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, announced today that Spinach STIX ® , its latest innovation in its popular line- [...]
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
06/05/2026
Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 – Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients enrolled; [...]
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
06/05/2026
Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.) TONMYA (cyclobenzaprine HCl sublingual [...]
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
06/05/2026
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™ ) planned for the second quarter of 2026 Initiation [...]

Pages